Timothy Franxman, MD
Allergy & Immunology · Louisville, KYNPI 1730306820
Payments from drug & device makers
Across 827 payments — averaging $195.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$143K
- Novartis$6K
- Sanofi$4K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$521
- plus $4K from 30 others
What the payments were for
- Consulting fees$12,0837%
- Speaking & faculty fees$127,50079%
- Grants$480%
- Travel & lodging$3,6502%
- Food & beverage$18,23911%
- Education$2680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 267 | $143,047 |
| Novartis | 60 | $6,187 |
| Sanofi | 126 | $4,194 |
| AstraZeneca | 78 | $2,195 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,344 |
| CSL Behring | 27 | $521 |
| Amgen | 38 | $475 |
| Biocryst US Sales Co., LLC | 24 | $458 |
| Kaleo, Inc. | 24 | $417 |
| Grifols USA, LLC | 16 | $357 |
| Pfizer | 20 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $284 |
| Teva Pharmaceuticals USA, Inc. | 21 | $264 |
| Optinose US, Inc. | 10 | $254 |
| Genentech USA, Inc. | 8 | $237 |
| Blueprint Medicines Corporation | 7 | $190 |
| Sanofi-aventis U.S. LLC | 2 | $152 |
| Alk-abello, Inc | 6 | $132 |
| AbbVie | 5 | $97 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $96 |
| Covis Pharma GmbH | 5 | $91 |
| Lilly USA, LLC | 2 | $55 |
| Boehringer Ingelheim | 3 | $51 |
| Ionis Pharmaceuticals, Inc. | 2 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Pharming Healthcare, Inc. | 2 | $41 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| GC Biopharma USA, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Organon | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,787 in reported general payments places this provider in the 85th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 37 | $155,595 |
| Dupixent SyringeDupilumab | 22 | $83,879 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $61,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $48,363 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $36,942 |
| XolairOmalizumab | 11 | $30,469 |
| Epinephrine | 95 | $22,772 |
| XhanceFluticasone Propionate | 19 | $11,553 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,448 |
| Montelukast Sodium | 453 | $2,760 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,219 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,114 |
| Fluticasone Propionate | 125 | $1,502 |
| Azelastine Hcl | 43 | $1,061 |
| Ipratropium Bromide | 33 | $869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $143,047 | $85,304102 claims |
| Grifols USA, LLCXembify | $357 | $61,80213 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $22,77295 claims |
| Optinose US, Inc.Xhance | $254 | $11,55319 claims |
| AstraZenecaBreztri Aerosphere | $2,195 | $9,44813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Louisville
- James SublettLouisville$1.7M
- James SublettLouisville$481K
- Stephen PollardLouisville$463K
- Douglas LotzLouisville$199K
- Jeremy JonesLouisville$149K
- Mark CorbettLouisville$138K
- Kali GeraceLouisville$30K
- David PallaresLouisville$22K
- Joseph TurbyvilleLouisville$13K
- Stuart WhiteLouisville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.